World's Best Scientists 2026 revealed!
Christian Kollmannsberger

Christian Kollmannsberger

D-Index & Metrics

Medicine

D-Index
84
Citations
40293
World Ranking
14848
National Ranking
615

Overview

Christian Kollmannsberger is affiliated with the University of British Columbia in Canada. Their research primarily focuses on medical and biomedical fields, with a significant emphasis on oncology and related areas.

The scientist's main fields of study include Medicine and Biochemistry, Genetics and Molecular Biology. Within these, their subfields cover Pulmonary and Respiratory Medicine, Oncology, Surgery, Molecular Biology, and Cancer Research. These subfields reflect a broad but interconnected scope centered around understanding and treating complex diseases, particularly cancers.

Kollmannsberger's contributions span several specific research topics, including:

  • Renal cell carcinoma treatment
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Renal and related cancers
  • Testicular diseases and treatments
  • Bladder and Urothelial Cancer Treatments
  • Economic and Financial Impacts of Cancer

Their publication record shows frequent contributions to widely recognized oncology and clinical journals. The most common publication venues include:

  • Journal of Clinical Oncology
  • Canadian Urological Association Journal
  • Annals of Oncology
  • The Oncologist
  • Clinical Cancer Research

Among recent works, several papers stand out:

  • "Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial," 2020, ESMO Open
  • "Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma," 2020, Annals of Oncology
  • "Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial," 2020, Cancer
  • "Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma," 2022, Cancer
  • "Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial," 2020, Journal for ImmunoTherapy of Cancer

Christian Kollmannsberger has collaborated extensively with several co-authors, who often work on related topics in oncology and cancer treatment research. Frequent co-authors include Lori Wood, Toni K. Choueiri, Lucia Nappi, Georg A. Bjarnason, and Naveen S. Basappa.

Best Publications

  • Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Bernard Escudier;David F. McDermott;Saby George

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini

  • Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Mark A. Warren

  • External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Lauren C. Harshman

  • Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Osvaldo Arén Frontera

  • European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I

    Susanne Krege;Jörg Beyer;Rainer Souchon;Peter Albers

  • European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)

    H. J. Schmoll;R. Souchon;S. Krege;P. Albers

  • Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

    Daniel Y.C. Heng;J. Connor Wells;Brian I. Rini;Benoit Beuselinck

  • Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

    Matti Annala;Matti Annala;Gillian Vandekerkhove;Daniel Khalaf;Sinja Taavitsainen

  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.

    Laurence Albiges;Nizar M. Tannir;Mauricio Burotto;David McDermott;David McDermott

  • Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

    Andrew J Armstrong;Susan Halabi;Tim Eisen;Samuel Broderick

  • Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

    Hans J. Hammers;Elizabeth R. Plimack;Jeffrey R. Infante;Brian I. Rini

  • The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy

    Toni K. Choueiri;Wanling Xie;Christian Kollmannsberger;Scott North

  • Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer

    C Bokemeyer;CC Berger;JT Hartmann;C Kollmannsberger

  • Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.

    T.K. Choueiri;R.J. Motzer;B.I. Rini;J. Haanen

  • Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy

    Lorch A;Beyer J;Bascoul-Mollevi C

  • Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials

    Chris Coppin;Christian Kollmannsberger;Lyly Le;Franz Porzsolt

  • Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance

    Christian Kollmannsberger;Torgrim Tandstad;Philippe L. Bedard;Gabriella Cohn-Cedermark

  • Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.

    Daniel J Khalaf;Matti Annala;Sinja Taavitsainen;Sinja Taavitsainen;Daygen L Finch

Frequent Co-Authors

Toni K. Choueiri
Toni K. Choueiri Harvard University
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Kim N. Chi
Kim N. Chi BC Cancer Agency
Georg A. Bjarnason
Georg A. Bjarnason Sunnybrook Health Science Centre
Thomas Powles
Thomas Powles Queen Mary University of London
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Sun Young Rha
Sun Young Rha Yonsei University
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Lawrence H. Einhorn
Lawrence H. Einhorn Indiana University
Robert Huddart
Robert Huddart Institute of Cancer Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The path to a medical career in the USA is diverse, and many students discover rewarding options beyond medical school. Online programs can be an excellent way to start or advance your healthcare journey.

Prospective nurses can take advantage of online nursing courses, which offer a flexible, cost-effective introduction to core concepts and patient care. Those who are already registered nurses may want to pursue their bachelor's degree through affordable rn to bsn programs, boosting career prospects and increasing earning potential.

For those interested in advanced practice, there are numerous online nurse practitioner programs available, preparing graduates for specialized roles and more autonomy in clinical environments. Ambitious nurses looking to reach the highest level of nursing practice should consider the cheapest dnp programs to earn a Doctor of Nursing Practice degree.

These online pathways offer affordability, flexibility, and a variety of entry points into the healthcare field—helping you tailor your education and career to your goals.

Best Scientists Citing Christian Kollmannsberger

Trending Scientists

Recently Published Articles